Form 4: Teva Pharmaceutical Director Sells 286,000 Shares

Roberto Mignone, a director at Teva Pharmaceutical Industries, sold 286,000 ordinary shares at a weighted average price of $22.0071 on December 20, 2024.

Summary

• Roberto Mignone, a director of Teva Pharmaceutical Industries, sold 286,000 ordinary shares on December 20, 2024.
• The shares were sold at a weighted average price of $22.0071, with individual transaction prices ranging from $21.82 to $22.075.
• Mignone also indirectly owns 695,000 ordinary shares through Swiftcurrent Master Fund, Ltd., where he is the manager of the investment advisor, Bridger Management, LLC.
• Mignone disclaims beneficial ownership of these 695,000 shares except to the extent of his indirect pecuniary interest.

Sentiment

Score: 4

Explanation: The document details a significant share sale by a director, which could be interpreted negatively by the market, although it is a routine disclosure. The disclaimer of beneficial ownership of the indirectly held shares adds a layer of complexity.

Negatives

• A director selling a significant number of shares could be perceived negatively by the market.

Risks

• The sale of a large block of shares by a director could potentially put downward pressure on the stock price.
• The market may interpret the sale as a lack of confidence in the company's future prospects by the director.

Management Comments

• Mr. Mignone disclaims beneficial ownership of the Ordinary Shares held of record by the Fund except to the extent of his indirect pecuniary interest therein.

Industry Context

Insider trading activity is closely monitored in the pharmaceutical industry, and large sales by directors can sometimes influence investor sentiment.

Comparison to Industry Standards

• It is common for directors to trade shares in their companies, but the size and timing of these transactions are often scrutinized.
• Comparable companies in the pharmaceutical sector also have directors who buy and sell shares, and these transactions are typically disclosed through SEC filings.

Stakeholder Impact

• Shareholders may react to the director's share sale, potentially impacting the stock price.
• The sale could influence investor confidence in the company.

Key Dates

Keywords

Teva Pharmaceutical, Roberto Mignone, insider trading, share sale, director, ordinary shares, Swiftcurrent Master Fund